Since 2010, multiple CAR-T cell clinical trials have been conducted targeting CD19 (CD19-CAR-T cells) to promote clinical responses in acute lymphoblastic leukemia (ALL) [98,99], diffuse large B-cell lymphoma (DLBCL) [100], chronic lymphocytic leukemia (CLL) [101], and other non-Hodgkin’s B-cell lymphomas [102], with remissions of up to 90% in some cases. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.